Glioblastoma
Conditions
Brief summary
Overall Survival (OS): Time from randomization to death from any cause., Progression-Free Survival (PFS): Time from randomization to disease progression (per RANO criteria) or death, whichever occurs first.
Detailed description
Objective Response Rate (ORR): Proportion of patients achieving a complete or partial response per RANO criteria., Duration of Response (DOR): Time from the initial response to disease progression or death in patients who respond to treatment., Safety and Tolerability: Incidence of adverse events (AEs), serious adverse events (SAEs), and treatment-related discontinuations, assessed according to NCI CTCAE v5.0 criteria.
Interventions
Sponsors
Pauls Stradins Clinical University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS): Time from randomization to death from any cause., Progression-Free Survival (PFS): Time from randomization to disease progression (per RANO criteria) or death, whichever occurs first. | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR): Proportion of patients achieving a complete or partial response per RANO criteria., Duration of Response (DOR): Time from the initial response to disease progression or death in patients who respond to treatment., Safety and Tolerability: Incidence of adverse events (AEs), serious adverse events (SAEs), and treatment-related discontinuations, assessed according to NCI CTCAE v5.0 criteria. | — |
Countries
Latvia
Outcome results
None listed